SubHero Banner
Text

October 2024

Core topics in this month’s edition include:

  • Vyalev™ (foscarbidopa/foslevodopa) – new drug approval
  • Pavblu™ (aflibercept-ayyh) - new biosimilar
  • Opdivo® (nivolumab) - new indication

Download PDF

Text